Skip to main content

Impact of administration timing of subanesthetic doses of esketamine on emergence agitation in patients undergoing nasal endoscopic surgery: a randomized controlled trial

In brief

Esketamine near surgery's end cuts agitation from 41% to 10%

In a randomized trial of nasal surgery patients, agitation occurred in 10% given esketamine 20 minutes before surgery ended, compared with 41% given placebo; giving it at anesthesia induction did not significantly reduce agitation. Pain, recovery time and adverse events were similar across groups. The single-center finding needs confirmation in larger, multicenter studies.

Journal
Frontiers in medicine (Q1)
Published
28 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Xiaolan Wen, Wei Sun, Wenhui Chen, Longmei Guo, Yan Zhang, Shutong Lv, et al.
PMID
43016697
DOI
10.3389/fmed.2026.1978040

Why clinicians should know about it

Abstract

INTRODUCTION: Emergence agitation (EA) is a common complication following general anesthesia, particularly after nasal endoscopic surgery with nasal packing. This study investigated whether the administration timing of subanesthetic esketamine influences its efficacy in preventing EA. METHODS: In this randomized, double-blind, placebo-controlled trial registered at the China Clinical Trial Registry (No. ChiCTR2500115004), 108 adult patients undergoing elective nasal endoscopic surgery were randomized (1:1:1) to receive intravenous normal saline (Group C), esketamine 0.25 mg.kg⁻1 during anesthesia induction (Group E1), or esketamine 0.25 mg.kg⁻1 20 min before surgical completion (Group E2). The primary outcome was the incidence of EA in the post-anesthesia care unit (PACU), defined as a Riker Sedation-Agitation Scale (SAS) score ≥ 5. Secondary outcomes included SAS scores, postoperative NRS pain scores, hemodynamics, and adverse events. RESULTS: Ninety-five patients completed the study (Group C: n = 32; Group E1: n = 32; Group E2: n = 31). Baseline characteristics were comparable across groups. The overall EA incidence differed significantly among groups (13/32 [40.6%] in C, 8/32 [25.0%] in E1, 3/31 [9.7%] in E2; P = 0.018). Group E2 had a significantly lower EA incidence (absolute risk reduction [ARR], 30.9%, [95% CI, 11.0%-50.9%]; number needed to treat [NNT], 3.2 [95% CI, 2.0-9.1]; P = 0.011) and lower SAS scores (adjusted P = 0.016) than Group C, whereas Group E1 showed no significant difference compared with Group C (P = 0.287). Postoperative pain scores, rescue analgesia, extubation time, PACU stay, hemodynamic stability, and adverse event rates were comparable across all groups. CONCLUSIONS: The preventive effect of subanesthetic esketamine on EA is timing-dependent. Administration 20 min before the end of surgery (0.25 mg.kg⁻1 IV) significantly reduces EA incidence in nasal endoscopic surgery patients. However, this single-center finding requires multicenter validation, and NRS scales remain limited in capturing packing-related suffocation discomfort. CLINICAL TRIAL REGISTRATION: identifier ChiCTR2500115004.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.